U.S. flag An official website of the United States government
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Update to Voluntary Recall of Eliquis® (apixaban) 5 mg Tablets (#HN0063) - Recall to retail/dispensing level only
  1. Recalls, Market Withdrawals, & Safety Alerts


Update to Voluntary Recall of Eliquis® (apixaban) 5 mg Tablets (#HN0063) - Recall to retail/dispensing level only

This recall has been completed and FDA has terminated this recall.

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement


Company Announcement Date:
FDA Publish Date:
Product Type:
Reason for Announcement:
Recall Reason Description
Potential Labeling Issue
Company Name:
Bristol-Myers Squibb
Brand Name:
Brand Name(s)
Bristol-Myers Squibb
Product Description:
Product Description
Eliquis (apixaban) 5 mg Tablets

Company Announcement

On June 10, Bristol-Myers Squibb announced a voluntary recall of one lot (#HN0063) of Eliquisdisclaimer icon 5 mg tablets. This lot was distributed nationwide in the U.S. to wholesalers and retail pharmacies in February 2017. Bristol-Myers Squibb is taking this precautionary measure based on a single customer complaint that a bottle labeled as Eliquis5 mg was found to contain Eliquis 2.5 mg tablets. No other lots are impacted by this recall.

This recall is to the retail/dispensing level and not to the consumer level. This recall is under way and is currently being executed. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Patients should not stop taking Eliquis without consulting with their physician

Please see Eliquis U.S. Full Prescribing Information, including Boxed WARNINGSdisclaimer icon.

For any customer or patient questions, please call:

General and Medical Inquiries Bristol-Myers Squibb Customer Information Center
Recall Logistics FedEx Supply Chain
Reimbursement/Replacement Process FedEx Supply Chain

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Additional Bristol-Myers Squibb Contacts:

Media: Ken Dominski, 609-252-5251, ken.dominski@bms.com
InvestorsTim Power 609-252-7509timothy.power@bms.com

Previous related recall: Bristol-Myers Squibb Voluntarily Recalls One Lot of Eliquis (apixaban) 5 mg Tablets


See table below


Ken Dominski


Back to Top